| Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer | Science advances |  | | 2025 | 95 | 232 |
|
| Unraveling cytotoxic tumor-specific CD4 T cells for advanced clinical applications | |  | | 2024 | 272 | 0 |
|
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy | Cell | | | 2024 | 1,009 | 417 |
|
| Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability | Frontiers in immunology | | | 2023 | 121 | 92 |
|
| Dendritic cells direct circadian anti-tumour immune responses | Nature | | | 2023 | 806 | 231 |
|
| The era of cytotoxic CD4 T cells | Frontiers in immunology | | | 2022 | 220 | 277 |
|
| Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer | Science Advances | | | 2021 | 500 | 464 |
|
| Impact of immunotherapy on CD4 T cell phenotypes and function in cancer | Vaccines | | | 2021 | 265 | 238 |
|
